Check out the companies that made headlines in intraday trading: Intel — The struggling chip stock rebounded toward the end of the year, rising nearly 1.2% in intraday trading. Intel could plummet more than 60% in 2024, giving the stock its worst year ever and the second-worst performance in the S&P 500. Nvidia — The artificial intelligence giant and retail investor favorite fell 1.3% as traders took profits as the trading year ended. With an increase of over 170%, Nvidia is poised to become the third-best performing stock in the S&P 500 in 2024. Gene therapy for hemophilia A. Sangamo retained the rights to the product. Biohaven — The biopharmaceutical stock soared nearly 2% after board member John Childs said he was buying 29,000 shares. Childs currently owns approximately 6.5 million shares. NutriBand — Shares rose more than 8% after NutriBand announced it expects the review process for its abuse-deterrent opioid patch, AVERSA Fentanyl, to be expedited. This could allow the company to receive regulatory approval by the end of 2025. This comes after NutriBand announced last week. The company announced that it has extended its patented technology in China to Macau. Zivo Bioscience — Shares rose nearly 3% after investor Mark Strome, who owns a 10% stake in the biotechnology research and development company, bought 75,000 shares. —CNBC’s Sean Conlon, Yun Li and Pia Singh contributed reporting.
